Zydus Lifesciences (BOM:532321) Total Liabilities: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:532321 Zydus Lifesciences Ltd BOM:532321
95 GF Score
Price ₹1,118.00
GF Value ₹1,220.21
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Zydus Lifesciences Total Liabilities?

Zydus Lifesciences BOM:532321 -0.97% 95 Total Liabilities is ₹0 Mil as of Jun. 2026. GuruFocus rates BOM:532321 with a GF Score™ of 95/100 and a GF Value™ of ₹1,220.21 (Fairly Valued). The stock has 3 warning signs investors should review.

Zydus Lifesciences's Total Liabilities for the quarter that ended in Jun. 2026 was ₹0 Mil.

Zydus Lifesciences's quarterly Total Liabilities increased from Dec. 2025 (₹0.00 Mil) to Mar. 2026 (₹228,244.00 Mil) but then declined from Mar. 2026 (₹228,244.00 Mil) to Jun. 2026 (₹0.00 Mil).

Zydus Lifesciences's annual Total Liabilities increased from Mar. 2024 (₹71,792.00 Mil) to Mar. 2025 (₹108,433.00 Mil) and increased from Mar. 2025 (₹108,433.00 Mil) to Mar. 2026 (₹228,244.00 Mil).

Zydus Lifesciences Total Liabilities Historical Data

* Premium members only.

The historical data trend for Zydus Lifesciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zydus Lifesciences Total Liabilities Chart

Zydus Lifesciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 87,416.00 60,681.00 71,792.00 108,433.00 228,244.00

Zydus Lifesciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 188,074.00 0.00 228,244.00 0.00
BOM:532321
95GF Score
Zydus Lifesciences Ltd BOM:532321
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zydus Lifesciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Zydus Lifesciences's Total Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=157119+(38563+28109
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+4453+0)
=228,244

Total Liabilities=Total Assets (A: Mar. 2026 )-Total Equity (A: Mar. 2026 )
=524066-295822
=228,244

Zydus Lifesciences's Total Liabilities for the quarter that ended in Jun. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=N/A

Total Liabilities=Total Assets (Q: Jun. 2026 )-Total Equity (Q: Jun. 2026 )
=N/A-N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of ₹0 Mil mean?
Zydus Lifesciences (BOM:532321) has a Total Liabilities of ₹0 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Zydus Lifesciences and its competitors.
Is Zydus Lifesciences' Total Liabilities too high?
Zydus Lifesciences' current Total Liabilities is ₹0 Mil. Overall, Zydus Lifesciences has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zydus Lifesciences' Total Liabilities compare to ZTS?
Zydus Lifesciences' Total Liabilities of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Zydus Lifesciences and its competitors. Zydus Lifesciences's current Total Liabilities is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zydus Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Zydus Lifesciences (BOM:532321) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,220.21, compared to a current price of ₹1,118.00 — trading 8.4% below its estimated fair value. The current Total Liabilities is ₹0 Mil. Zydus Lifesciences' overall GF Score™ is 95/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Zydus Lifesciences (BOM:532321), the current Total Liabilities is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zydus Lifesciences (BOM:532321) Overvalued in 2026?

Based on GuruFocus' analysis, Zydus Lifesciences stock appears to be undervalued. The current stock price of ₹1,118.00 is trading 8.4% below its estimated GF Value™ of ₹1,220.21. GuruFocus considers Zydus Lifesciences to be Fairly Valued.

Key valuation signals for BOM:532321:

  • Total Liabilities: ₹0 Mil
  • GF Value™: ₹1,220.21 vs. price of ₹1,118.00 (8.4% below fair value)
  • GF Score™: 95/100 with 3 warning signs

No single metric tells the full story. See the BOM:532321 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zydus Lifesciences Business Description

Other Exchanges ZYDUSLIFE:India
Address Scheme No. 63, Sarkhej-Gandhinagar Highway, Zydus Corporate Park, Survey No. 536, Near Vaishnodevi Circle, Khoraj (Gandhinagar), Ahmedabad, GJ, IND, 382481
Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. It is engaged in the research, development, production, marketing, and distribution of pharmaceutical products. The product portfolio of the company includes Active Pharmaceutical Ingredients (API), human formulations, animal health and veterinary, and consumer health and wellness products. Its products are marketed under brands like Amlodac, Inditel, Pivasta, and others. The company's operating segments are: Pharmaceuticals, which derives key revenue, and Consumer products. Geographically, it generates maximum revenue from the United States, followed by India, and other countries.
95GF Score

Get the complete analysis for BOM:532321

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,118.00
Price
₹1,220.21
GF Value